Sep 30, 2021
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption
Acacia Pharma has created a portfolio of differentiated hospital products primarily for use by anesthesiologists and a promising late-stage development candidate targeting oncologists.
Acacia Pharma plans to commercialize its current pipeline products directly in the US via its own commercial organization targeting anaesthesiologists and oncologists.Partnering
Acacia Pharma is a commercial stage biopharmaceutical group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.Investors